Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia

Affiliations

Comment

Jorge J Castillo et al. JAMA Oncol. 2018.

. 2018 May 1;4(5):744-745.

doi: 10.1001/jamaoncol.2017.0734.

¹ Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

No abstract available

Comment in

Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia-Reply.
Kapoor P, Gertz MA, Ansell SM. Kapoor P, et al. JAMA Oncol. 2018 May 1;4(5):745-746. doi: 10.1001/jamaoncol.2017.5100. JAMA Oncol. 2018. PMID: 29392293 No abstract available.

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Kapoor P, et al. JAMA Oncol. 2017 Sep 1;3(9):1257-1265. doi: 10.1001/jamaoncol.2016.5763. JAMA Oncol. 2017. PMID: 28056114 Free PMC article. Review.